BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boyd A, Lacombe K, Miailhes P, Gozlan J, Bonnard P, Molina JM, Lascoux-Combe C, Serfaty L, Gault E, Desvarieux M, Girard PM. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 2010;17:65-76. [PMID: 19682317 DOI: 10.1111/j.1365-2893.2009.01153.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother. 2014;15:1337-1349. [PMID: 24773464 DOI: 10.1517/14656566.2014.913571] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
2 Yurdaydin C, Idilman R. Therapy of Delta Hepatitis. Cold Spring Harb Perspect Med 2015;5:a021543. [PMID: 26253093 DOI: 10.1101/cshperspect.a021543] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
3 Piroth L, Pol S, Lacombe K, Miailhes P, Rami A, Rey D, Loustau-ratti V, Morlat P, Goderel I, Sene D, Rosenthal E, Carrat F, Cacoub P. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study. Journal of Hepatology 2010;53:1006-12. [DOI: 10.1016/j.jhep.2010.04.041] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
4 Boyd A, Kouamé MG, Houghtaling L, Moh R, Gabillard D, Maylin S, Abdou Chekaraou M, Delaugerre C, Anglaret X, Eholié SP, Danel C, Zoulim F, Lacombe K; ANRS 12136 Temprano and ANRS 12240 VarBVA studies. Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan Africa. Trans R Soc Trop Med Hyg 2019;113:437-45. [PMID: 31574151 DOI: 10.1093/trstmh/trz021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31-40. [PMID: 20051970 DOI: 10.1038/nrgastro.2009.205] [Cited by in Crossref: 254] [Cited by in F6Publishing: 198] [Article Influence: 21.2] [Reference Citation Analysis]
6 Lo Re V, Wang L, Devine S, Baser O, Olufade T. Hepatic decompensation in patients with HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy. Clin Infect Dis. 2014;59:1027-1031. [PMID: 24944235 DOI: 10.1093/cid/ciu476] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
7 Katwesigye E, Seremba E, Semitala F, Ocama P. Low sero-prevalence of hepatitis delta antibodies in HIV/ hepatitis B co-infected patients attending an urban HIV clinic in Uganda. Afr Health Sci 2016;16:1089-93. [PMID: 28479902 DOI: 10.4314/ahs.v16i4.26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
8 Mudawi H, Hussein W, Mukhtar M, Yousif M, Nemeri O, Glebe D, Kramvis A. Overt and occult hepatitis B virus infection in adult Sudanese HIV patients. International Journal of Infectious Diseases 2014;29:65-70. [DOI: 10.1016/j.ijid.2014.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
9 Béguelin C, Moradpour D, Sahli R, Suter-Riniker F, Lüthi A, Cavassini M, Günthard HF, Battegay M, Bernasconi E, Schmid P, Calmy A, Braun DL, Furrer H, Rauch A, Wandeler G; Swiss HIV Cohort Study. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. J Hepatol 2017;66:297-303. [PMID: 27746337 DOI: 10.1016/j.jhep.2016.10.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
10 Aghasadeghi MR, Mohraz M, Bahramali G, Aghakhani A, Banifazl M, Foroughi M, Ahmadi F, Eslamifar A, Sadat SM, Ramezani A. Frequency and Genotype of Hepatitis D Virus Infection in Patients Infected with HIV and Those Undergoing Hemodialysis. Hepat Mon 2013;13:e7481. [PMID: 23914228 DOI: 10.5812/hepatmon.7481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
11 Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73-85. [PMID: 21511329 DOI: 10.1016/s0140-6736(10)61931-9] [Cited by in Crossref: 316] [Cited by in F6Publishing: 125] [Article Influence: 28.7] [Reference Citation Analysis]
12 Hallinan R, Osborn M, Cohen M, Dobbin M, Wodak A. Increasing the benefits and reducing the harms of prescription opioid analgesics: Prescription opioids: harms and benefits. Drug and Alcohol Review 2011;30:315-23. [DOI: 10.1111/j.1465-3362.2011.00294.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
13 Schewe K, Noah C, Sirma H, Schmiedel S, van Lunzen J, Rockstroh JK, Schildgen O. Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report. Viruses 2010;2:1564-70. [PMID: 21994693 DOI: 10.3390/v2081564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Soriano V, Grint D, d'Arminio Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit S, Lundgren J, Rockstroh J, Peters L. Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011;25:1987-92. [PMID: 21857493 DOI: 10.1097/QAD.0b013e32834babb3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
15 Hønge BL, Jespersen S, Medina C, Té Dda S, da Silva ZJ, Lewin S, Østergaard L, Erikstrup C, Wejse C, Laursen AL, Krarup H; Bissau HIV cohort study group. Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS One 2014;9:e99971. [PMID: 24915064 DOI: 10.1371/journal.pone.0099971] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
16 Kabaçam G, Onder FO, Yakut M, Seven G, Karatayli SC, Karatayli E, Savas B, Idilman R, Bozdayi AM, Yurdaydin C. Entecavir treatment of chronic hepatitis D. Clin Infect Dis. 2012;55:645-650. [PMID: 22573857 DOI: 10.1093/cid/cis459] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
17 Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, Winters M, Glenn JS, Kirk GD, Segev DL, Nelson KE, Marks M, Heller T, Golub ET. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202:845-852. [PMID: 20701536 DOI: 10.1086/655808] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 5.2] [Reference Citation Analysis]
18 Katwesigye E, Seremba E, Semitala F, Ocama P. Low sero-prevalence of hepatitis delta antibodies in HIV/ hepatitis B co-infected patients attending an urban HIV clinic in Uganda. Afr Health Sci 2017;17:974-8. [PMID: 29937867 DOI: 10.4314/ahs.v17i4.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]